Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $11.16B | +7.8% | $1.08B | $0.61 | -19.7% | 56.2% | 12.1% |
| Q4 2025 Dec 2025 | $11.46B | +4.4% | $1.78B | $1.01 | — | 57.1% | 19.6% |
| Q3 2025 Sep 2025 | $11.37B | — | $1.64B | $0.94 | — | 55.4% | 18.1% |
| Q2 2025 Jun 2025 | $11.14B | — | $1.78B | $1.01 | — | 56.4% | 18.4% |
| Q1 2025 Mar 2025 | $10.36B | — | $1.33B | $0.76 | — | 56.9% | 16.3% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can Abbott Laboratories' upgraded full-year outlook sustain this massive double-digit stock rally, or is the relief surge short-lived?